Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

Table 1 BTK inhibitors for hematologic malignancies

BTK inhibitor	Indication: FDA approval	Indication: China approval
Ibrutinib	CLL/SLL, WM, R/R MZL, R/R MCL	China: CLL/SLL, R/R MCL, WM Hong Kong: CLL/SLL, R/R MCL, WM Taiwan: CLL/SLL, R/R MCL, WM, R/R MZL
Acalabrutinib	CLL/SLL, R/R MCL	China: R/R MCL; R/R CLL/SLL Hong Kong: CLL/SLL, R/R MCL Taiwan: CLL/SLL, R/R MCL
Zanubrutinib	CLL/SLL, WM, R/R MCL, R/R MZL	China: CLL/SLL, WM, R/R MCL Hong Kong: CLL/SLL, WM, R/R MCL Taiwan: CLL/SLL, WM, R/R MCL, R/R MZL
Orelabrutinib	None	China: R/R MCL, R/R CLL, R/R MZL
Tirabrutinib	R/R PCNSL	Taiwan: R/R PCNSL
Pirtobrutinib	R/R MCL	None

Cutoff date: September 2023
In 2023, ibrutinib voluntarily withdraws the indication for MCL in patients who have received at least 1 prior therapy and for MZL in patients who require systemic therapy and have received at least 1 prior anti-CD20-based therapy, due to requirements related to accelerated approval status granted by the FDA
BTK, Bruton tyrosine kinase; CLL, chronic lymphocytic leukemia; FDA, Food and Drug Administration; MCL, mantle cell lymphoma; MZL, marginal zone B-cell lymphoma; PCNSL, primary central nervous system lymphoma; R/R; relapsed/refractory; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia

ISSN: 2162-3619